• POLICY ANALYSIS 
  HTA as a Basis for Reimbursement and Priorities in Health Care: European and Industry Perspective
  Priority Decisions - The Authority Challenge
  The New National Institute of Health and Clinical Excellence (NICE) Single Technology Appraisal (STA) Process: Experience from the First Completed Appraisals
• PRESIDENT'S MESSAGE
  Are We There Yet? - The Impact of Pharmacoeconomics and Outcomes Research on Decision Making
• ISPOR CORNER
  Great Research or Lack of Training

• POLICY ANALYSIS 
  Reimbursement of Drugs in Germany: A Road Map for the Approval Process
• PRESIDENT'S MESSAGE
  Being International: More Than A Question of Geography?
• OUTCOMES ASSESSMENT
  A Collaborative Approach to Patient-Reported Outcome (PRO) Instrument Development: The EXACT-PRO Initiative
• ECONOMIC EVALUATION
  The Missing Link: Managing Missing Data in Economic Evaluations
• ISPOR Board of Directors Take Action in 2006

• POLICY ANALYSIS :
  Risk-Benefit Analysis Methods for Pharmaceutical Decision-Making - Where Are We Now?
• PRESIDENT'S MESSAGE
  International Guidelines for Pharmacoeconomics Analyses - Vive La Différerence?
• OUTCOMES ASSESSMENT
  Pills and Productivity: What Economic Theory Tells Us About Employees' Work Behaviors
• ECONOMIC EVALUATION
  Approaches to Estimating Maximum Study Power for Economic Endpoints in Fixed Sample Size Designs
• ISPOR 9th Annual European Congress: Asking Critical Questions ISPOR 9th Annual European Congress Scientific Award Winners

• ECONOMIC EVALUATION
  Pharmacoeconomics and Market Access in Europe: Case Studies in Scotland and The Netherlands
• PRESIDENT'S MESSAGE
  Credibility in Health Services Research: What day of the week is it?
• POLICY ANALYSIS
  The German IQWiG - It's not NICE Benefit assessment in Germany-new sense or nuisance?
• OUTCOMES ASSESSMENT
  Balancing Affordability and Value: The Universal Challenge in Health Care Delivery

• President's Message
• Health Care Decision Makers Facing the Budget Allocation Dilemma: Compressing Mortality vs. Compressing Morbidity
• Designing and Developing Budget Impact Models Suited for Global Adaptation
• Multi-National Assessment of Outcomes Via Retrospective Databases

• Outgoing Presidential Address
• ISPOR 11th Annual International Meeting: Returning to Where it All Began!
• ISPOR 11th Annual International Meeting Award Recipients
• ISPOR 11th Annual Meeting Photo Gallery
• Understanding Patient Adherence and its Economic Consequences
• The New Effective Health Care Program at AHRQ
• ISPOR Comments on the Guidance for Industry - Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims

• ISPOR 2nd Asia-Pacific Conference: Expanding ISPOR In Asia & Beyond
• Presidential Fireside Chat: Postcard from Shanghai
• ISPOR 2nd Asia-Pacific Conference: Significance for China
• ISPOR 2nd Asia-Pacific Conference Best Contributed Podium and Poster Award Recipients
• The Value of Safety: A Critical Issue All Along the Development and Marketing of Pharmaceuticals

• Avoiding Bias and Standardizing Costs in Formulary Decisions
• Presidential Fireside Chat: ISPOR Initiatives in Communication and Outreach
• Regulations of Drug Reimbursement Decisions In Hungary
• Use of the Propensity Score Matching Method to Reduce Recruitment Bias in
  Observational Studies: Application to the Estimation of Drotrecogin Alfa's Impact on
  Intensive Care Units Workload
• ISPOR Board Of Directors Take  Action In 2005

• The Application of Post-Market Registries and Other Evidence for Medical Devices
• President’s Fireside Chat: Monitoring the Quality of Our Society
• The Application of Post-Market Registries and other Evidence for Medical Devices - Part I: FDA Perspective: What is FDA’s Experience with Post Approval Development Studies? What is the Primary Evidentiary Role of these Studies?
• The Application of Post-Market Registries and other Evidence for Medical Devices - Part II: US Center For Medicare & Medicaid Services (CMS) Perspective: What Is CMS’s View On The Role Of Post-Market Evidence In Coverage For Medical Device?
• The Application of Post-Market Registries and other Evidence for Medical Devices - Part III: Post-Market Studies Under Medicare Coverage with Evidence Development: When Are They the Wrong Answer to the Right Question?
• Use of Patient Registries: Results of the ISPOR Patient Registry Special Interest Group Survey
• ISPOR 8th Annual European Congress: Ciao, Firenze!
• ISPOR 8th Annual European Congress Scientific Awards Winners

• Modelling the Use of Hospital Services as a Function of Needs and Supply in Italy for Capitation Purpose
• Utilizing Patient Registries to Support Health Economics Research: Integrating Observational Data with Economic Analyses, Models, and Other Applications
• ISPOR Risk Management Special Interest Group - A Plan For Action
• President’s Fireside Chat: Keeping an “I” on ISPOR’s Mission
• Issues in the Design of Database Studies: A Focus on Selection Bias
• ISPOR Japan Chapter Opens Door to the Next Stage in Asia-Pacific
• ISPOR Avedis Donabedian Outcomes Research Lifetime Achievement Awardee: Kathleen N. Lohr, PhD
   

• Incoming Presidential Address
• The $64,000 Questions: What Are We Willing to Pay for a QALY?
• Alternative to the Fourth Hurdle: Clinical and Cost-Effectiveness Analyses in Europe: Bridging the Gap Between Science, Industry and Policy Makers
• ISPOR Comments on the Draft Guideline Factors CMS Considerations in
  Making a Determination of Coverage with Evidence Development
  
   

• ISPOR 10th Annual International Meeting-10 Years of Excellence!
• ISPOR Tenth Annual Awards Recipients
• ISPOR 10th Annual International Meeting Photo Gallery
• ISPOR Comments on the Medicare Rx Data Elements

• The $64,000 Question: What Are We Willing To Pay for a QALY.
• President’s Fireside Chat
• Board of Directors Election 2005
• ISPOR Student Corner

• Quality Adjustment Using Average Utilities: Virtue or Vice?
• Comparison of Reimbursement Systems of Various Countries in Central and Eastern Europe, Africa, Middle East and Asia
• President’s Fireside Chat
• The $64,000 Question: What Are We Willing to Pay for a QALY
• Boards of Directors Take Action in 2004
   

• ISPOR 7th Annual European Congress Destination: Hamburg, Germany
• ISPOR 7th Annual European Congress Photo Gallery
• ISPOR 7th Annual European Congress Scientific Awards Winners
• President’s Fireside Chat

• Use and Misuse of the Case-Control Methodology in Economic Analyses
• The Continuing Evolution of Patient Registries: Designing Programs to Meet Broad
  Organizational Objectives
• Issues in the Use of Patient Reported Outcomes in Medical Device Trials: A Report on the “ISPOR Medical Device Forum: Patient Reported Outcomes (PROs) in Device Evaluation: Scientific and Regulatory Challenges”, May 18, 2004, Arlington, VA, USA
• President’s Fireside Chat
• Let’s Get Talking…New Initiatives to Facilitate Communication Among ISPOR Researchers
• ISPOR Avedis Donabedian Outcomes Research Lifetime Achievement Awardee:
  Michael F. Drummond PhD

• Incoming Presidential Address
• Publication of Pharmacoeconomic Data Submitted to Reimbursement or Clinical Guidelines Agencies
• Pharmacoeconomic Guidelines Around The World

• Outgoing Presidential Address
• Short Courses Again Popular Prior to the 9th Annual Meeting
• 9th Annual International Meeting Photo Gallery
• ISPOR 9th Annual International Meeting Awards Recipients
• ISPOR 9th Annual Meeting Summary

• In Search of an Unbiased Estimate of Treatment Effect Using Observational Data: A Comparison of Propensity Scoring and Heckman Two Stage Sample Selection Models
• Use of Outcomes Research in Pharmaceutical Medical and Reimbursement Decisions in a Decentralized System
• Measuring the Gains from Medical Research: An Economic Approach

• “Bridging the Gap” – Relating Patient Reported Outcomes (PROs) to Decision-Makers
• Are the Health Economic Guidelines Suitable for the Assessment of New Drugs in Children’s Diseases?
• What Exactly Do You Mean By That? A Summary of Discrepancies in the Definitions of Key Pharmacoeconomic and Outcomes Research Terms – A White Paper
• Survey of Pharmacoeconomic Assessment Activity in Eleven Countries
• A Web-based Registry of Cost-Utility Analyses
• Boards of Directors Take Action in 2003

Adobe Acrobat PDF Format

• More than 1100 Attendees Travel to Barcelona for ISPOR 6th Annual European Congress
• Short Courses Again Popular at ISPOR 6th Annual European Congress
• ISPOR Sixth Annual European Congress Scientific Awards Winners
• ISPOR 6th European Congress Photo Gallery
• ISPOR Leadership Retreat Participants Take Action on ISPOR Vision 2005
• Presidents Fireside Chat

Adobe Acrobat PDF Format

• Landmark ISPOR Asia Pacific Conference Opens Door to ISPOR Future in Asia-Pacific
• Use Of Iterative Search Strategies To Increase PubMed Yield For Pharmacoeconomic Research
• Best Practices: Evaluating Modeling Research at ISPOR Using BMJ and ISPOR Guidelines
• Evaluating Retrospective Study Design Posters Presented at the ISPOR 7th Annual International Meeting, May 19-22, 2002, Arlington, VA, USA
• Survey of Acceptable Variations in Cost-effectiveness Ratios: A Brief Overview

• Incoming Presidential Address
• Discounting Health Effects in Pharmacoeconomic Evaluations: Some Additional Elements to Consider
• "Aut Diem" - Saving Drug Costs Does Not Mean Savings in Total Health Care Costs
• Out-of-Pocket Payments in Belgium: An Analysis in Relation to Pathology
• ISPOR Vision 2010 Committee Needs Your Feedback!

• Outgoing President’s Address - A Lot Happens in an ISPOR Year
• ISPOR 8th Annual International Meeting: Another Meeting, Another Success
• Short Courses Again Popular Prior to the 8th Annual Meeting
• ISPOR 8th Annual International Meeting Awards Recipients
• 8th Annual International Meeting Photo Gallery

• Medical or Public Health Registries-Evidence of Impact on Standards for  Health Care
  in the US
• Patient-Reported Outcomes Information Technology: The PROsIT ™  System
• Health Care System in China and its Acceptance of Pharmacoeconomics and Outcomes Research
• ISPOR President's Fireside Chat
• Fourth Russian Congress: Pharmacoeconomics at the Turn of the Century
• China Hosts the First Pharmacoeconomic International Forum for Medical Insurance Executive members in Shanghai

• Applying the Sciences to Decision-Making: A Practical Approach [Formulary Decision Making: PART 2 of 2]
• Use Of Diagnosis Related Groups (DRG) In Estimating Costs
• PBAC Signals Its Intention To Publish Its Negative Recommendations
• Pharmacoeconomic & Outcomes Research Internship Employer Survey Results
• Fireside Chat
• Boards of Directors Take Action in 2002
• ISPOR Code of Ethics for Researchers

• Fireside Chat: The Future Belongs to the People Who Plan It
• Dimensions of Formulary Decision Making
• Methods for Collecting Patient-Reported Outcomes
• Patients Don’t Take Their Medications…Now What Do We Do?
• FDA Actions Against Misleading Or Unsubstantiated Economic And Quality-Of-Life Promotional Claims: An Analysis of Warning Letters and Notices of Violation

• Incoming Presidential Address
• Pharmacoeconomics: Why Should Actuaries Care?
• The Life Cycle Model: a Framework for the On-Going Evaluation of a PRO Instrument
• Item Response Theory and Its Applications to Patient-Reported Outcomes Measurement
• What is Next for Outcomes Research in Asia? An Issues Panel Discussion

• ISPOR 7th Meeting summary
• ISPOR 7th Meeting Short Course summary
• ISPOR 7th Meeting Awards Recipients
• ISPOR 7th Meeting Photo Gallery
• Assessing Pharmacoeconomic and Quality of Life Outcomes in Global Patient Registries

• Healthcare Databases with Longitudinal Patient Data in Europe
• Patients’ Willingness to Pay for Pharmacist Managed Warfarin Therapy at Community Pharmacies
• Number Needed to Treat (NNT): Is it a Useful Benchmark for the Efficiency of Therapies?
• Pharmacoeconomic Fellowship Survey

• Joel Hay ‘Steps Down’ as Editor-in-Chief of VALUE IN HEALTH and ISPOR Board of Directors Begins Search for New Editor
• The Use of Multi-attribute Analyses, Multi-dimensional Scaling and Pairwise Comparisons for Group Decision-Making
• Boards of Directors Take Action in 2001
• The ISPOR Board of Directors endorses the following Statement of the World Association of Medical Editors (WAME), May 2001
• Articles: Bridging the gap
  between users and producers of health economic studies